Trump's 200% tariff plan may be a bitter pill for US consumers, warns Dr Reddy's

The United States plans significant tariffs on imported generic medicines. These duties will rise to 200% in the coming years. Dr Reddy's Laboratories anticipates higher medicine prices for American consumers. Shifting manufacturing to the US is currently considered impractical by the company. India faces substantial exposure as a major generic medicine exporter to the US.